US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bulletin from the extraordinary general meeting on 23 October 2024 in Chosa Oncology AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.   Today, on 23 October 2024, an extraordinary general meeting was held in Chosa Oncology AB. A summary of the adopted resolutions follows below.   Election of new board member as well as remuneration for the new board member The extraordinary general meeting resolved in accordance with the proposal from Buhl Krone Holding ApS (“Buhl Krone”) to elect Fred R. Hirsch as new board member alongside the current board

Notice of annual general meeting in Chosa Oncology AB

The shareholders of Chosa Oncology AB, Reg. No. 559037-2271, are invited to attend the annual general meeting to be held on Friday 31 May 2024 at 1.00 p.m. at Medicon Village, in the main building the Spark, conference room Collaboraction, Scheeletorget 1, Lund, Sweden.Right to participate and notification Shareholders wishing to participate in the annual general meeting must: · partly be listed in the company’s share register kept by Euroclear Sweden AB as of Thursday 23 May 2024; and · partly have notified their participation no later than on Monday 27 May 2024 by post to Chosa

CHOSA has carried out a directed issue of SEK 5,58 million to fund KOL-initiated DRP validation studies and to increase business development activities

The board of CHOSA Oncology AB (publ) ("CHOSA" or the "Company") has today, 3. April 2024, performed a directed issue of 6 070 233 shares at a price of SEK 0,92 per share. The subscription price per share has been set under market conform conditions based upon Volume Weighted Average Price (VWAP) over a period of 10 trading days up to and including 2. April  2024, which was the last trading day for the share before the Board of Director’s decision on the Directed Issue. This will increase the number of shares from 64 873 913 to 70 944 146. In anticipation of the Directed Issue, the board

Chosa Oncology – Appoints Chief Commercial Officer and new Chief Financial Officer

28 March 2024 CHOSA Oncology – today announced the appointment of Claus Frisenberg Pedersen as Chief Commercial Officer and Gerton Jönsson as the new Chief Financial OfficerAs part of CHOSA’s enforced focus on Business Development Claus Frisenberg Pedersen will dedicate his full attention to business development in CHOSA. Consequently, Gerton Jönsson has been appointed as the new CFO and will start right away. Gerton has more than 20 years of experience in financial management, including CFO experience with listed companies within the life science sector.   Peter Buhl Jensen,

CHOSA Oncology AB’s postpones publication of the interim report Q4 2024

CHOSA Oncology announced today, 8th February 2024, the decision to postpone the release of its interim report for the fourth quarter of 2024. The previously communicated publication date of Friday, February 9, 2024, will be rescheduled to Thursday, February 29, 2024.The company's performance throughout the fourth quarter has been in alignment with expectations and remains in accordance with the established financial plan. Operations have been executed in line with projections, and current funding is secured through the fourth quarter of 2024. The delay in publishing the quarterly report is

CHOSA Oncology AB receives tax credit of 7.8 mSEK

CHOSA Oncology AB (publ) ("CHOSA" or the "Company") has as expected received the tax credit from the Danish ”Tax Credit Order” of 5.1 mDKK equivalent to 7.8 mSEK. The tax credit is equal to the tax value of the expenses attributable to research and development in the 2022 financial year of Rhovac ApS. The received tax credit is in line with previously communicated assumptions.CEO Peter Buhl comments: “We are happy to announce that the Danish tax authorities have now refunded the expenses as applied for, used for clinical development. The funds will support CHOSA’s Business development and

CHOSA Oncology AB has carried out a directed issue of SEK 1,55 million to further increase business development activities

The board of CHOSA Oncology AB (publ) ("CHOSA" or the "Company") has today, 13[th] October 2023, performed a directed issue of 2 099 280 shares at a price of SEK 0,738 per share. The reason for the deviation from conducting a shareholders’ preferential rights issue has been to raise capital in a time-efficient manner. The subscription price per share has been set under market conform conditions based upon Volume Weighted Average Price (VWAP) over a period of 10 trading days up to and including 12. October  2023, which was the last trading day for the share before the Board of Director’s

CHOSA Oncology AB’s postpones publication of the interim report Q2

CHOSA Oncology announced today, 27[th] August 2023, the decision to postpone the release of its interim report for the second quarter of 2023. The previously communicated publication date of Monday, August 28, 2023, will be rescheduled to Thursday, August 31, 2023.The company's performance throughout the second quarter has aligned with expectations and remains in accordance with the established financial plan. Operations have been executed in line with projections, and current funding is secured through the second quarter of 2024. The delay in publishing the quarterly report is attributed

ASCO 2023 - good news for CHOSA

· Immuno Oncology with PD1 inhibitors successful in NSCLC in combination with cisplatin. · CHOSA’s DRP has the potential to turn this combination into precision therapy. CHOSA Oncology AB ("CHOSA") presents highlights from the American Society of Clinical Oncology (ASCO) in a video on the homepage.Listen to CEO Peter Buhl Jensen’s presentation here  Previously communicated abstract on LiPlaCis data presented at ASCO can be found here  .

BioStock: Chosa develops next generation chemotherapy

The chemotherapy cisplatin has been a staple in cancer treatment since the 1980s. However, not all cancer patients respond to the drug, and the side effects are quite severe. Chosa Oncology is looking to tackle both of these drawbacks with its iCIP concept. BioStock has taken a closer look at this revolutionary cancer treatment and how the company is working to take it to the next level.Read the full article at biostock.se : https://www.biostock.se/en/2023/06/chosa-develops-next-generation-chemotherapy/ This is a press release from BioStock - Connecting

CHOSA Oncology AB publishes results from clinical phase 2 trial of liposomal formulation in breast cancer, using predictive marker for cisplatin

[En bild som visar text, skärmbild, Teckensnitt, nummer Automatiskt genererad beskrivning]   CEO Peter Buhl comments: “CHOSA presents these important findings that have crystallized by deep clinical knowledge and years of dedication to developing LiPlaCis and its response prediction test DRP”.   We welcome interaction and look forward to discussing this at the ASCO poster session that opens today:   Abstract number and title: 3130; Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancerSession: Developmental

Bulletin from the annual general meeting on 26 May 2023 in Chosa Oncology AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on 26 May 2023, the annual general meeting was held in Chosa Oncology AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and distribution of the company’s profitThe annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The annual general meeting  also resolved to

CHOSA Oncology AB presents clinical phase 2 results of LiPlaCis and its Drug Response Predictor test at ASCO 2023

CHOSA Oncology AB today publishes results from the prospective phase 2 study of LiPlaCis® (a liposomal formulation of cisplatin) in previously heavily treated patients with metastatic breast cancer as the abstract is being released on the ASCO website on May 25, 2023, at 5:00 PM (ET) / 23:00 CET (please see a link to ASCO’s website below). This patient group was tested using the diagnostic tool Drug Response Prediction (DRP®), which is a 205 mRNA biomarker signature, that assesses whether the patient is likely to respond to cisplatin treatment - or not. The results show that patients who get

CHOSA Oncology AB out-license clinical-stage cancer vaccine candidate to Magle Group

CHOSA Oncology AB, today announces that the company has out-licensed the clinical-stage therapeutic cancer vaccine candidate onilcamotide to Magle Group. Magle Group plans to further develop onilcamotide by use of its proprietary degradable starch microspheres (DSM) technology. The company sees a future potential to combine onilcamotide treatment with its already approved vascular embolic product EmboCept® S.Onilcamotide is a clinical-stage therapeutic cancer vaccine candidate targeting RhoC, an over-expressed protein in metastatic cancer cells. Onilcamotide is a peptide that forms a

CHOSA Oncology AB announces approved re-listing memorandum

CHOSA Oncology AB (publ) ("CHOSA" or the "Company"), formerly RhoVac, announces that Spotlight Stock Market ("Spotlight") today approved the relisting memorandum that the Company was required to draw up in connection with the Company's reverse acquisition of the Danish CHOSA ApS.The approval of the re-listing memorandum also confirms that Spotlight considers CHOSA to meet all current listing requirements. As a result, trading in the Company's shares will be re-listed on the ordinary list.CHOSA, which through the reverse acquisition of CHOSA ApS now owns the licensing rights to the drug

CHOSA Oncology AB publishes annual report 2022

CHOSA Oncology AB (publ) announces today that the company is publishing its annual report for 2022. The annual report has been approved for issue by the board and CEO on May 2, 2023 and will be subject to approval at the annual general meeting on May 26, 2023. The annual report and consolidated accounts for the financial year 2022 are available at the company's website (www.chosaoncology.se), on Spotlight Stock Market's website (www.spotlightstockmarket.com) and at the company's office (c/o Medicon Village AB, Scheeletorget 1, 223 81 Lund)..

Notice of annual general meeting in Chosa Oncology AB

The shareholders of Chosa Oncology AB, Reg. No. 559037-2271, are invited to attend the annual general meeting to be held on Friday 26 May 2023 at 09.00 a.m. at Medicon Village, in the main building the Spark, conference room Collaboraction, Scheeletorget 1, Lund, Sweden.Right to participate and notification Shareholders wishing to participate in the annual general meeting must: · partly be listed in the company’s share register kept by Euroclear Sweden AB as of Wednesday 17 May 2023; and · partly have given a notice of their intent to participate to the company no later than on

CHOSA Oncology AB payback of convertible loan in process - update

CHOSA Oncology AB has as previously announced initiated the process of payback of the convertible loan of 14,98 mSEK (plus interest) SEK which RhoVac obtained from shareholders to support the development of RV001. The process is unfortunately more complex than anticipated, which causes a delay. There have been many questions about the calculation of the interest and below is a clarification.The original loan was 24.979.760 SEK, and a partial refund of 10.000.000 SEK was paid back on August 29[th], 2022. The interest rent is 10% and CHOSA will pay 5 months of interest on the full amount and

CHOSA Oncology AB payback of convertible loan in process

CHOSA Oncology AB has initiated the process of payback of the convertible loan of 14,98 mSEK (plus interest) which RhoVac obtained from shareholders to support the development of RV001 and which will be balanced by the EU grant from Horizon 2020. The process is unfortunately more complex than anticipated, which causes a delay. The payback is in process, and we expect to have it concluded within the coming week(s)CEO Peter Buhl comments: “The initiation process in ongoing but has unfortunately caused us more administrative challenges than we had hoped for. I want to apologize for any

CHOSA Oncology AB's abstract Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer accepted at 2023 ASCO Annual Meeting

CHOSA Oncology a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP[®] companion diagnostics for personalized cancer care, today announced that an abstract with the title ‘Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer’ has been accepted for a poster presentation at the world’s biggest and prestigious cancer conference  American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023 in Chicago, USA.CEO Peter Buhl will present the data at the ASCO meeting taking

CHOSA Oncology AB initiates payment of last portion of loan given to RhoVac AB

CHOSA Oncology AB has initiated the payment of final portion of the loan of 10 MSEK and interest which RhoVac AB obtained from shareholders to support the development of RV001.CEO Peter Buhl commenting: “After several administrative steps CHOSA has initiated the pay back process to fulfill our obligations towards the loan givers. I want to thank you all for your patience and for your support in developing products for hard-to-treat cancers.”

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe